Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
Update
With gene expression Without gene expression Mutation & CNV Plot
Summary

Searching Database & Compiling the results...

This process involves analyzing complex genetic data and may take a moment.




PDX model details

PDX ID 435.1A Cx
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Castrate
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
 17 (13*)
Average PDX Generation Time (days +/- SEM) 56 ± 2
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen or cryopreserved tissue)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304
Markers 435.1A Cx
AR N
PSA N
PSMA N
NE Y
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
435.1A Cx TCERG1 0.612 3.056 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx GEMIN5 0.547 2.922 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx IGF2R 0.600 3.031 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx PIK3CB 1.182 4.537 Gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx TP53 -28.584 4.970e-09 Homdel MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx MGA -1.045 0.970 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx ERBB4 -0.881 1.086 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx ZNRF3 -1.004 0.997 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx ZNRF3 -1.228 0.854 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx FANCA -1.266 0.831 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx FANCA -1.097 0.935 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx ZFHX3 -0.959 1.029 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx ZFHX3 -0.822 1.131 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx CDH1 -1.209 0.865 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx CUL3 -0.881 1.086 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx RB1 -1.328 0.797 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx BRCA2 -0.961 1.028 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx USP28 -1.027 0.982 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx SUFU -0.979 1.015 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx APC -0.953 1.033 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx CHD1 -0.953 1.033 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx SMARCAD1 -0.843 1.115 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
435.1A Cx CUL3 -1.085 0.943 Loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19

Clinical Information

Sample Number 435.1A
Sample Site Right temporal fossa
Sample source Autopsy
Pathology Tumour Diagnosis None
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc) 0.0
Treatment Prior to Specimen Collection ADT, carboplatin plus etoposide

Patient Information

Patient Number 435
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) 16.2
Consent to share data Yes, subject to ethical review

Patient Tumour Collection (Current Model)
Tumour sample ID 435.1A
Patient Age (binned in 5 year age groups) 65-69
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
435.1A Cx ZFHX3 277 1.0 Missense variant '4/10 1.63E-05 32 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
435.1A Cx BRCA2 216 1.0 Frameshift variant '11/28 . . - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
435.1A Cx SUPV3L1 590 0.65 Missense variant '13/15 . 31 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
435.1A Cx PRKDC 294 0.51 Missense variant '1/87 . 24.9 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
435.1A Cx TSHR 492 0.49 Missense variant '11/11 . 27.2 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
435.1A Cx NTRK2 397 0.49 Missense variant '10/21 . 27.3 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
435.1A Cx NOTCH3 402 0.44 Missense variant '33/33 1.28E-05 28.5 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
435.1A Cx IRF4 419 0.44 Missense variant '3/9 3.66E-05 21.5 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
435.1A Cx NOTCH2 490 0.41 Frameshift variant '34/34 . . - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
435.1A Cx ATAD2B 443 0.33 Missense variant '1/28 . 25.1 - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500